Verified

Scientific Leadership Development Award

HIV Vaccine Trials Network

The HVTN anticipates a marked increase in HIV vaccine trials in our pipeline in the next several years. This has led to a continuing need to ensure a new generation of scientific leaders is ready to move vaccine trials forward.

The Scientific Leadership Development program will identify these emerging leaders of the HVTN and commit resources to their professional development with the goal of expanding the pool of early career scientists capable of successfully leading HIV vaccine clinical trials.

Successful candidates have a reputation for excellence at their clinical sites, have strong interest in research, and have a career trajectory likely to lead to protocol chair or cochair roles.

A key goal of the program is to develop first author capacity. Applicants with an extensive first-author publication record are therefore not a good fit for this program.

General Program Details

Each scientist will create a professional development plan, complete a scientific manuscript using HVTN data, and receive coaching and sponsorship. The overarching goal is that candidates will achieve readiness to co-chair or chair HVTN protocols upon program completion. Scientists will be supported through their affiliate sites with up to 20% FTE for the duration of the program. In addition, scientists may be eligible for travel scholarships, publication fees, and other support to advance their scholarly work while enrolled in the program.

The HVTN will solicit applications annually from interested scientists, and will fund up to 6 scientists every year through this program.

AI Based Application Success Predictor

1. ⭐⭐⭐⭐⭐ Direct contribution to preventive HIV vaccine development

This is the central success predictor.

HVTN's mission is specifically to advance a safe and effective preventive HIV vaccine. Research should therefore address a meaningful bottleneck in vaccine development rather than merely study HIV biology in general.

Strong proposals should clearly establish:

What vaccine-development problem is being addressed?
What scientific uncertainty prevents progress?
How will the proposed study resolve that uncertainty?
How could the result influence the next vaccine-development decision?

Strong chain:

Vaccine problem → scientific gap → experiment/trial → immune/clinical evidence → vaccine-development decision

2. ⭐⭐⭐⭐⭐ Strong scientific significance and innovation

HVTN supports research intended to answer critical questions in HIV vaccine development, including work on novel vectors, inserts, proteins, adjuvants, delivery methods and vaccine combinations.

Innovation can involve:

New vaccine platforms.
Novel immunogens.
New prime/boost strategies.
Novel adjuvants.
New delivery approaches.
New immune correlates.
New statistical methods.
New biomarker approaches.
New trial designs.

A strong project should explain why the proposed approach could solve a problem that existing approaches have not solved.

3. ⭐⭐⭐⭐⭐ Ability to answer a decisive scientific question

HVTN's clinical-trial infrastructure is designed around answering specific questions rather than conducting research simply because a vaccine candidate is available.

Historical and current HVTN priorities include:

Phase I safety/immunogenicity studies.
Phase II candidate evaluation.
Iterative "fast-track" studies.
Phase IIb/III efficacy trials.
Immune correlates of protection.
Host and viral genetic variability.
Vaccine-induced immune responses.

Therefore, a strong proposal should identify a decision-changing question.

For example:

Does this immunogen generate the immune response needed to justify advancing it to the next stage?

or:

Does this biomarker reliably distinguish immune responses associated with protection?

4. ⭐⭐⭐⭐⭐ Strong immunology and mechanistic rationale

HIV vaccine research requires a particularly strong understanding of how vaccination produces potentially protective immunity.

HVTN's research achievements include development and standardization of assays for neutralizing antibodies and HIV-specific T-cell responses, as well as statistical methods for analyzing vaccine-induced immune responses.

Strong proposals should connect:

Vaccine intervention → immune mechanism → measurable immune response → potential protection

Potentially important areas include:

Broadly neutralizing antibodies (bnAbs).
T-cell immunity.
Germinal-center responses.
Antibody breadth and potency.
Mucosal immunity.
Fc-mediated functions.
Immune correlates.
Viral diversity and immune escape.
Systems vaccinology.

5. ⭐⭐⭐⭐⭐ Clinical-trial rigor and statistical strength

Because HVTN conducts clinical studies across multiple phases and sites, methodological rigor is essential.

The network incorporates dedicated statistical and data-management expertise, centralized laboratory capabilities and standardized assays to allow comparisons across vaccine candidates and studies.

A strong clinical proposal should address:

Appropriate study design.
Sample-size justification.
Statistical analysis.
Randomization/blinding where appropriate.
Safety monitoring.
Immunogenicity endpoints.
Appropriate laboratory assays.
Predefined decision criteria.
Handling of missing data.
Multiplicity and interim analyses where applicable.

For exploratory/ancillary studies, the analysis should still be sufficiently rigorous to produce interpretable results.

6. ⭐⭐⭐⭐⭐ Potential to advance candidates through the development pipeline

A major HVTN strength is the ability to move from early-stage testing to efficacy evaluation.

The network's research agenda historically includes:

Phase I → Phase II → Phase IIb/III → efficacy → immune correlates → vaccine development

with candidate advancement based on predefined criteria.

Therefore, strong research should explain its developmental consequence.

For example:

Successful Phase I result → candidate advances to Phase II.

or:

Immune correlate identified → enables prioritization of vaccine candidates.

or:

Improved immunogen → provides rationale for a subsequent clinical trial.

7. ⭐⭐⭐⭐☆ Global relevance and diverse populations

HVTN's mission is explicitly to develop a vaccine effective globally, and the network has conducted clinical research internationally.

Strong proposals should consider:

Geographic HIV diversity.
Viral clades/subtypes.
Population-specific immune responses.
Sex and age where scientifically relevant.
Epidemiological differences.
Local healthcare and trial infrastructure.
Global implementation considerations.

This is particularly important because an HIV vaccine must work against substantial viral and host diversity.

HVTN's research agenda explicitly includes assessment of host and viral genetic variability and its impact on immunogen response and efficacy.

8. ⭐⭐⭐⭐☆ Meaningful community engagement and participant-centered research

HVTN is not solely a laboratory/clinical network. Its structure includes participants and communities, and its scientific programs address perceptions of vaccine research, willingness to participate, recruitment, retention, adherence and acceptance of effective interventions.

A strong clinical proposal should therefore consider:

Community engagement.
Participant understanding.
Recruitment feasibility.
Retention.
Visit adherence.
Acceptability.
Communication of research results.
Ethical considerations.

For vaccine efficacy research, scientific success depends heavily on the ability to recruit and retain participants appropriately.

9. ⭐⭐⭐⭐☆ Strong collaboration and access to HVTN infrastructure

HVTN is explicitly structured as a multidisciplinary collaboration involving:

Clinical investigators.
Immunologists.
Laboratory scientists.
Statisticians.
Data managers.
Community representatives.
Regulators.
Ethicists.
Industry.
Government.

Researchers proposing work through HVTN should demonstrate why their team and network resources are appropriate.

For ancillary/exploratory studies, HVTN can provide access to data and specimens from its studies for qualified research questions related to vaccinology, immunology, HIV/AIDS and other infectious diseases.

10. ⭐⭐⭐⭐☆ Early-career potential and leadership development

HVTN has an explicit infrastructure for developing the next generation of HIV vaccine scientists.

Its current programs include:

Scientific Pilot Awards
Research and Mentorship Program (RAMP)
Scientific Leadership Development
Translational HIV Vaccine Early Stage Investigator Conference.

The Scientific Pilot Awards are specifically designed for early-stage investigators conducting research at their own sites.

For these mechanisms, reviewers should see:

Clear career-development value.
Mentorship.
Increasing scientific independence.
A coherent HIV-vaccine research direction.
Potential to become a future HVTN scientific leader.

Specialties

Infectious Diseases

Public Health

Leadership and Administration

Eligibility Requirements

MD, PhD, or equivalent doctoral degree
Track record of work on HVTN clinical trials
Current affiliation with HVTN Core site or site with active HVTN studies
Need for mentoring in one or more key areas: first authorship, protocol development, protocol implementation, translational research and immunology, statistical analysis
A local HVTN mentor who can oversee their progress

Sponsor Details

Sponsor Institute/Organizations: HIV Vaccine Trials Network

Sponsor Type: Corporate/Non-Profit

Address: 1100 Fairview Ave. N., P.O. Box 19024, Seattle, WA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity